Prof Sir Menelas N Pangalos DSc PhD FRSB FMedSci HonFBPhS on AstraZeneca’s new Discovery Centre (DISC) in Cambridge (25 February 2022)

Prof Sir Menelas N Pangalos DSc PhD FRSB FMedSci HonFBPhS on AstraZeneca’s new Discovery Centre (DISC) in Cambridge (25 February 2022)

“Drug discoverer. Science lover. Combining both as Exec VP at AstraZeneca to transform how we understand and tackle diseases and treat patients in a digital age” (Sir Menelas “Mene” Pangalos on Twitter)

On Friday 25 February 2022 at 5:00pm (Tokyo time), 8:00am (London/Cambridge time) Sir Menelas Pangalos, Exec Vice-President & President BioPharmaceuticals R&D at AstraZeneca, and leading the creation of AstraZeneca’s new R&D Centre in Cambridge, has very kindly agreed to join us for a zoom discussion about health, the pharma industry, and AstraZeneca’s new Discovery Centre (DISC) in Cambridge.

All Trinity College Cambridge Fellows, former Fellows, students, alumni and members very welcome.

  • 5pm (5pm Tokyo time, 8am UK time)- start
  • 5:15pm – 6:00pm Sir Menelas Pangalos
  • 6:00pm – 7pm follow-on discussions

Prior registration required until Wednesday 23 February 2022. Anonymous registrations are not accepted, please introduce yourself briefly when you register. For security there is a two-step pre-registration/registration process. Only pre-registered and approved participants can join the zoom event.

We will upload the recording to the Trinity in Japan Youtube Channel – by participating you agree to the upload of the recording: 

https://www.youtube.com/trinityjapan?sub_confirmation=1

Prof Sir Menelas N Pangalos DSc PhD FRSB FMedSci HonFBPhS
EVP & President BioPharmaceuticals R&D

Sir Mene was appointed as Executive Vice-President, R&D BioPharmaceuticals in January 2019 and is responsible for BioPharmaceutical R&D from discovery through to late-stage development covering Cardiovascular, Renal, Metabolism, Respiratory, Immunology, Microbial Science and Neuroscience areas. Prior to this, he served as Executive Vice-President of AstraZeneca’s Innovative Medicines & Early Development Biotech Unit and Global Business Development.

Since joining AstraZeneca in 2010, Mene has led the transformation of R&D productivity through the development and implementation of the “5R” framework resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. Mene previously held senior R&D roles at Wyeth and GSK.

Mene holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge and is a Visiting Professor at The Wolfson Centre at Kings College. He co-chairs the UK Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also on the Boards of The Francis Crick Institute, The Judge Business School, Cambridge University and Dizal Pharma, and is a member of the Life Sciences Vision Advisory Group. Mene was awarded the 2019 Prix Galien Medal, Greece for his scientific research and named Executive of the Year at the 2019 Scrip Awards. In 2019, Mene was awarded the honour of a Knighthood by Her Majesty The Queen for his services to UK science. In 2021 Mene was awarded an Honorary Fellowship of the British Pharmacological Society.

Mene also oversees the creation of AstraZeneca’s new Global R&D Centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry which has started occupation this year.

Since the start of 2020, Mene has led and overseen AstraZeneca’s R&D response to COVID-19; maintaining existing clinical trials and delivery of medicines to patients, responding to the UK government’s call for supporting our national testing effort, and discovering and developing new preventative and treatment approaches to the disease. This work has involved partnering with Oxford University in the global development of a vaccine and ensuring broad an equitable access at no profit during the pandemic, the discovery and development of a long-acting antibody combination for those who can’t be vaccinated, as well as exploring our existing portfolio as potential treatment options against the disease.

AstraZeneca’s new Cambridge Discovery Centre (DISC)

https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html

More about Prof Sir Menelas N Pangalos:

“Our commitment is clear – fostering a culture that rewards pioneering science and asks the ‘killer’ questions. It’s how we push the boundaries of what’s possible” – from: https://www.astrazeneca.com/our-company/our-people/menelas-pangalos.html

https://en.wikipedia.org/wiki/Mene_Pangalos

AstraZeneca’s Mene Pangalos awarded knighthood in the New Year 2020 Honours List: https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-mene-pangalos-awarded-knighthood-in-the-new-year-2020-honours-list-28122019.html

Sir Menelas on Twitter:

“Drug discoverer. Science lover. Combining both as Exec VP at AstraZeneca to transform how we understand and tackle diseases and treat patients in a digital age”

Sir Mene Pengalos on Youtube

Cambridge Judge Business School CJBS Perspectives with Sir Mene Pangalos and Professor Stelios Kavadias
Bringing together minds to combat COVID-19 – Sir Mene Pangalos
GapSummit 2020 Keynote Q&A: Sir Mene Pangalos (Executive VP BioPharmaceuticals R&D, AstraZeneca)

Registration and enquiries:

All Trinity members, Fellows and students globally are very welcome to pre-register, and I will send a registration link if there are still places available.

In “Your message” box please state:

  1. which event(s) you are interested to attend,
  2. your full name, briefly introduce yourself if this is your first time to attend a Trinity in Japan event,
  3. your affiliation with Trinity College Cambridge – Trinity students, PhD students are especially welcome
    • If you are not associated with Trinity College Cambridge, you may still attend as a guest in certain cases – in this case please write a short sentence why you are interested to attend and participate in the discussion,

Thank you – we ask for your understanding that “anonymous” participation (eg name unknown to us, a free email eg hotmail / gmail / yahoo etc) is not possible. We cannot answer “anonymous” requests.

    Copyright (c) 2021 Trinity in Japan Society All Rights Reserved